​

Citius Pharmaceuticals (CTXR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CTXR Stock Rating

Citius Pharmaceuticals stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

CTXR Price Target Upside V Benchmarks

TypeNameUpside
StockCitius Pharmaceuticals-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.58$0.58$0.58
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-1---1
Aug, 26-1---1
Jul, 26-1---1
Jun, 26-1---1
May, 26-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 19, 2026H.C. WainwrightBuyBuyhold
May 23, 2025CitigroupBuyHolddowngrade
Dec 30, 2024CitigroupBuyupgrade
Aug 19, 2024EF HuttonBuyBuyhold
Jul 15, 2024EF HuttonBuyinitialise

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-5.76$-5.57$-5.97-----
Avg Forecast$-0.22$-4.00$-5.72$-1.84$1.36$2.50$3.60$4.44
High Forecast$-0.16$-4.00$-4.44$-1.43$1.91$3.44$5.07$6.27
Low Forecast$-0.26$-4.00$-8.07$-2.60$1.05$1.55$2.79$3.45
Surprise %2518.18%39.25%4.37%-----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported--------
Avg Forecast$103.16M-$61.72M$39.59M$125.20M$231.29M$344.98M$423.08M
High Forecast$120.48M-$81.26M$52.12M$164.84M$304.50M$454.18M$557.01M
Low Forecast$83.03M-$51.14M$32.80M$103.73M$191.62M$285.81M$350.51M
Surprise %--------

Net Income Forecast

$-2B $-900M $-300M $300M $900M $2B Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-33.64M$-32.54M$-39.14M$-39.74M----
Avg Forecast$-32.53M$-605.18M$-1.09B$-350.05M$258.10M$433.77M$625.02M$771.92M
High Forecast$-24.28M$-605.18M$-772.73M$-248.57M$332.93M$598.07M$882.22M$1.09B
Low Forecast$-39.63M$-605.18M$-1.40B$-451.54M$183.27M$269.48M$485.66M$599.81M
Surprise %3.42%-94.62%-96.40%-88.65%----

CTXR Forecast FAQ

Is Citius Pharmaceuticals stock a buy?

Citius Pharmaceuticals stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Citius Pharmaceuticals is a favorable investment for most analysts.

What is Citius Pharmaceuticals's price target?

Citius Pharmaceuticals's price target, set by 6 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.58.

How does Citius Pharmaceuticals stock forecast compare to its benchmarks?

Citius Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Citius Pharmaceuticals over the past three months?

  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Citius Pharmaceuticals’s EPS forecast?

Citius Pharmaceuticals's average annual EPS forecast for its fiscal year ending in September 2026 is $1.36, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $2.5 in 2027, $3.6 in 2028, and $4.44 in 2029.

What is Citius Pharmaceuticals’s revenue forecast?

Citius Pharmaceuticals's average annual revenue forecast for its fiscal year ending in September 2026 is $125.2M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $231.29M, followed by $344.98M for 2028, and $423.08M for 2029.

What is Citius Pharmaceuticals’s net income forecast?

Citius Pharmaceuticals's net income forecast for the fiscal year ending in September 2026 stands at $258.1M, representing a -749.47% decrease from the reported $-39.74M in 2025. Projections indicate $433.77M in 2027, $625.02M in 2028, and $771.92M in 2029.